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Gut hormones produced by gastrointestinal enteroendocrine cells modulate key 25 
physiological processes including glucose homeostasis and food intake, making them 26 
potential therapeutic candidates to treat obesity and diabetes. Understanding the function 27 
of enteroendocrine cells and the molecular mechanisms driving hormone production is a 28 
key step towards mobilising endogenous hormone reserves in the gut as a new therapeutic 29 
strategy. In this review we will discuss the variety of ex vivo and in vitro model systems 30 
driving this research and their contributions to our current understanding of nutrient 31 
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The gastrointestinal (GI) tract epithelium is produced by stem cells that differentiate into 64 
absorptive and secretory cell types including the rare hormone producing enteroendocrine 65 
cells (EECs). Taken as a whole, EECs make up the largest endocrine system in the body, with 66 
over 20 different gut hormones having been described. Classically EECs have been defined 67 
by which hormones they express and secrete (Figure 1), although it is now evident that 68 
individual EECs exhibit an unexpected degree of heterogeneity in hormone expression (1). 69 
Gut hormones play a number of roles in normal and disease physiology and are a major 70 
focus of academic and industrial research. The GI tract is exposed to ingested nutrients, 71 
circulating hormones/nutrients, and other GI components such as bile acids and bacterial 72 
metabolites. Many of these act as physiological stimuli that promote or inhibit hormone 73 
secretion from EECs (Figure 1). Once secreted, gut hormones can act locally in a paracrine 74 
manner and target other cells in the mucosa and local neuronal networks, or enter the 75 
bloodstream to reach distant organs. In this review we will highlight the different 76 
experimental models and tools used for EEC research. 77 
 78 
Model Tissues for Enteroendocrine Research 79 
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There are many models currently being used to investigate EECs. In this review we will 80 
concentrate on ex vivo and in vitro models. The majority of research in the field has been 81 
performed using animal tissues (mostly rodent and in particular murine) as these are readily 82 
available, relatively inexpensive, and make use of the multiple transgenic strains available. 83 
Ideally for research into the role of EECs in health, human tissue would be used, but this is 84 
restricted by tissue availability, practicalities and additional technical difficulties. Some 85 
studies have used pigs, as at is has been suggested they are a more relevant model for 86 
humans; unlike rodents, for example, they express the hormone motilin. However, there are 87 
key digestive differences between the two species, including increased GI fermentation in 88 
pigs which is likely to influence EEC hormone secretion. Pigs also have the disadvantage over 89 
rodents that due to their size, studies require larger facilities, more labour time and 90 
increased animal housing costs.  91 
 92 
Here we will discuss ex vivo model systems involving isolated intestinal perfusion and Ussing 93 
chambers, and in vitro models such as cell lines, short term primary cultures and intestinal 94 
organoids (Figure 2). The characteristics of each model with regard to throughput capability, 95 
tissue suitability, longevity etc have been summarised in Figure 2a.  96 
 97 
 98 
Ex vivo Studies 99 
Isolated intestinal perfusion and Ussing chamber systems are classic ex vivo models that 100 
have been widely used to investigate EEC function in different regions of the GI tract (2-10). 101 
Intestinal perfusion can be performed on animals as small as mice, and generally involve 102 
isolating a target gut segment whilst it is physically retained within the abdominal cavity, 103 
enabling vessel cannulation whilst the heart is still beating. The gut segment under 104 
investigation is defined by the area supplied by the cannulated artery, and the lumen can be 105 
additionally cannulated and perfused (Figure 2c). In further modifications, the method has 106 
been adapted to enable gut hormone sampling from the intestinal lymph (11). Perfused 107 
intestinal models can be used to monitor hormone secretion from different regions of the 108 
small intestine or the colon, and are a useful tool to study EECs in the context of their 109 
surrounding environment, as their local neuronal and vascular circuits largely remain intact, 110 
thus supporting near normal regulation of the EECs. The intestinal epithelial barrier is also 111 
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maintained, allowing luminal and systemic application of nutrients or drugs to identify their 112 
directionality of action. A blood substitute without red blood cells is commonly used for the 113 
vascular perfusion, allowing larger sample volumes and more frequent sampling than is 114 
possible in in vivo studies on mice, and thus better resolution of hormone secretory 115 
dynamics. Hormone secretion has also been measured from isolated intestinal loops 116 
mounted in liquid paraffin, which can be readily perfused via the gut lumen but not through 117 
the vasculature. This method relies on the detection of hormones after they have diffused 118 
through the muscular layers and serosa into the surrounding space where they collect in 119 
small aqueous pools adjacent to the paraffin (12). Although this is a simpler experimental 120 
setup than the vascularly perfused intestine, hormone diffusion is too slow to allow 121 
resolution of the time course of secretion, and the tissue is more prone to hypoxia due to 122 
the lack of continuous vascular perfusion with oxygenated medium. For obvious ethical 123 
reasons, isolated human intestinal perfusion studies are not possible, and most research is 124 
performed in rodents, or sometimes in pigs as they are considered a more human relevant 125 
model. Isolated intestinal perfusion studies involve highly specialised surgical techniques 126 
and are of low throughput compared with the in vitro models which are quicker, easier and 127 
can be scaled up to enable the parallel examination of multiple test conditions.  128 
 129 
Ussing chambers have also been extensively used to study hormone secretion from intact 130 
intestinal tissue pieces (2,6-10). This method involves mounting tissue segments in 131 
specialised chambers that were classically used to investigate mucosal physiology and 132 
pharmacology (Figure 2d). As with the perfused intestinal models, the epithelial barrier is 133 
maintained, enabling questions to be asked about whether drugs and nutrients target EECs 134 
from the luminal or basolateral direction (2,10). In this system the integrity of the tissue 135 
(epithelial barrier) can be assessed using electrodes which enable live assessment of the 136 
trans-epithelial resistance and potential difference of the mounted specimen. Hormone 137 
secretion in Ussing chamber studies can be monitored either by directly assaying hormone 138 
concentrations in the basolateral chamber, or by measuring the electrical properties of the 139 
epithelium which are altered when secreted hormones such as PYY and GLP-1 target their 140 
receptors on enterocytes or enteric neurones. Electrophysiological changes in response to 141 
cAMP elevation through forskolin/IBMX can also be used to assess the 142 
responsiveness/viability of the investigated tissue at the end of the experiment. When 143 
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hormone concentrations are measured in Ussing chambers by immuno-assay, optimisation 144 
of the chamber volumes and tissue size is required to ensure that hormone concentrations 145 
are not below the detection limit of the assay. It is also sometimes necessary to strip away 146 
the muscle layers to improve diffusion of hormones and stimuli between the EECs and the 147 
basolateral fluid compartment.  148 
 149 
A significant drawback of both these ex vivo systems is the limited experimental window 150 
during which the tissue remains healthy. Unlike in vitro models which can be kept for a few 151 
days in primary culture or maintained indefinitely as cell lines, the ex vivo model systems 152 
described above remain viable for only a few hours. Upper small intestinal tissue mounted 153 
in an Ussing chamber, for example, has been shown to become compromised after just 2 154 
hours, although more distal regions were slightly more resilient (13). This has contributed to 155 
a paucity of Ussing chamber studies examining EECs in the upper GI tract. Ussing chambers 156 
have been used to study human as well as mouse EECs, as the method only requires small 157 
tissues pieces that can be obtained under ethical approval from routine surgical operations 158 
that resect normal tissue as part of a clinical procedure. Nevertheless, studies on human 159 
intestine are limited by tissue availability and by the integrity of the epithelium, as human 160 
samples generally incur significant delays between tissue collection and experimentation 161 
(14).  162 
 163 
 164 
In Vitro Studies 165 
Historically, a basic cellular tool for many researchers has been cell lines - immortalised cells 166 
that can be routinely passaged and maintained, and scaled up for high throughput studies 167 
or experiments requiring large cell numbers. There are multiple cell lines used as models for 168 
EEC research, including GLUTag, NCI-H716, STC-1, HuTu-80 and BON cells. Several cell lines 169 
have been used as models for GLP-1 producing L-cells, including GLUTag, a murine 170 
endocrine tumour adherent cell line, STC-1, a rat adherent cell line and NCI-H716, a human-171 
derived suspension cell line (15-18). Multiple disadvantages are associated with the use of 172 
cell lines in research: many lines are derived from tumours and therefore have genetic and 173 
morphological differences from their in vivo counterparts, they are a simplified system and 174 
grown without other cell types present, and they lack many physiological traits of their 175 
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native counterparts with regards to cell morphology and polarity. At the transcriptomic level, 176 
GLUTag and STC-1 cells exhibited many similarities to native L-cells, but also a number of 177 
differences, including altered expression of key G-protein coupled receptors involved in L-178 
cell sensing (19,20). A recent analysis of different EEC cell lines also found substantial 179 
differences in hormone processing compared with native cells (18). Cell lines do, however, 180 
play an important role in EEC research, particularly for studies that require high cell 181 
numbers or high throughput.   182 
In the last decade, techniques and protocols have been developed for the use of primary 183 
EECs in research. A number of groups have measured hormone secretion from intestinal 184 
tissue biopsies, but responses to stimuli are relatively weak in this setting (14,21). In 2008, 185 
Reimann et al published the first protocol for the use of short lived (days) 2-dimensional (2D) 186 
primary cultures of the murine intestinal epithelium for studying EECs, which has recently 187 
been published as a video protocol ((22,23), Figure 2f). This method enabled, for the first 188 
time, assessment of primary L-cells by electrophysiology and calcium imaging techniques, 189 
combined with measures of hormone secretion. Since publication, this technique has been 190 
successfully applied to intestinal tissues from other species including human, and has 191 
supported the identification of many nutrient- and drug-activated pathways involved in the 192 
release of gut hormones from varying regions along the GI tract (2,6,7,20,24-26). Typical 193 
preparations from mouse or human tissue samples generate approximately one 24-well 194 
plate per 5-10cm length of mouse intestine, so this method allows several drug treatments 195 
to be tested in parallel, giving a relatively high experimental throughput compared with ex 196 
vivo studies. Whilst the protocol can potentially be scaled up to 96-well plates or beyond, 197 
the method is ultimately limited by the sensitivity of the immuno-assays used for hormone 198 
detection. The major drawbacks of this system are the short-lived nature of the culture, the 199 
isolation of EECs from some of the surrounding cell types, loss of apico-basal polarity and 200 
lack of the epithelial barrier. In cultures derived from the small intestine, EECs only survive 201 
for a few days, whereas EECs from the colon were still functional after 10 days (23). No new 202 
EECs appear to form under these culture conditions (22,23) so every preparation requires a 203 
fresh tissue sample, incurring associated animal costs and local availability of suitable 204 
mouse strains. Because these intestinal primary cultures do not generate an epithelial 205 
barrier or exhibit apico-basal polarity, they are not suitable for analysis of whether stimuli 206 
act via the apical or basolateral surface.  207 
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 208 
Once EECs have been completely separated from their neighbours by enzymatic or EDTA 209 
dispersal, they seem not to survive for long in culture, although calcium imaging was 210 
successfully performed in acutely isolated CCK-producing cells by flow cytometry based on 211 
their cell specific expression of GFP (27). By contrast, Raghupathi et al (2013) separated 212 
enterochromaffin cells, an EEC type that primarily secretes serotonin (Figure 2e), using a 213 
Percoll density gradient and generated a 95% pure population of enterochromaffin cells that 214 
could be kept in culture for up to 4 days with a 70% survival rate (28-30). The 215 
enterochromaffin cells isolated by this process have been assessed using amperometry, rt-216 
qPCR and calcium imaging. The drawbacks of this technique are similar to those described 217 
for primary intestinal cultures with the added uncertainty of the potential functional 218 
consequences of separating EECs from their neighbouring enterocytes.   219 
 220 
The use of GI organoids rather than primary cultures eliminates the need for a constant 221 
supply of freshly-harvested tissue (Figure 2g). Intestinal organoids are 3D structures grown 222 
from stem cells, and consist of organ-specific cell types that self-organise and show spatially 223 
restricted lineage commitment (31). These organoids are initiated from either pluripotent or 224 
adult stem cells and are grown in specialized media that mimic the stem cell niche. 225 
Protocols to generate intestinal organoids from embryonic or induced pluripotent stem cells 226 
are under development, but still require refinement to optimise the differentiation and 227 
maturation of EECs (32,33). It is relatively straight-forward, however, to produce organoids 228 
from adult intestinal stem cells, which are coerced to form organoids by creating conditions 229 
that mimic the stem cell niche environment deployed during tissue self-renewal or damage 230 
repair. Indeed, the intestine is a self-renewing tissue containing abundant adult crypt stem 231 
cells, and was one of the first tissues to be used to generate long term organoids from 232 
mouse and human (34,35). 3D organoids can be maintained in culture by regular splitting 233 
and re-plating, and can be cryopreserved in much the same way as a standard cell line. 234 
Depending on the intestinal region and species of origin, however, it is often necessary to 235 
change the culture conditions to promote the formation of fully differentiated EECs, and 236 
once they have been induced to form a terminally differentiated state containing functional 237 
EECs, organoid cultures generally have a limited survival of up to a week, thus resembling 238 
the behaviour of primary cultures derived from freshly-harvested tissue.  239 
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 240 
Intestinal organoids have recently been used to investigate EEC function and represent a 241 
promising model for EEC research (36,37). When generated from transgenic mouse models 242 
expressing fluorescent sensors and reporters driven by different gut hormone promoters, 243 
for example, they provide a replenishable source of identifiable EECs for single cell analysis. 244 
Organoid cultures have been shown to contain different types of EECs and to retain their 245 
regional identity with regard to the profile of gut hormones produced (38). Other studies 246 
have shown that EECs generated within intestinal organoids are responsive to a range of 247 
physiological stimuli and are secretion competent (36,37,39,40). Cells within 3D organoids 248 
have apico-basal polarity with their apical membranes located towards the organoid core. 249 
Apical surfaces are therefore largely inaccessible when stimuli are applied via the media, 250 
which is a potential limitation of the model as most nutritional stimuli first reach their target 251 
EECs in vivo via the gut lumen. However, experiments using dextran labelling have 252 
suggested that organoids are leaky and that solutions can readily reach the apical 253 
membrane (40). We recently developed a 2D plating method for intestinal organoids to 254 
facilitate patch clamp electrode access, cellular imaging within a single focal plane and 255 
measurements of GLP-1 secretion (36). Data from these studies showed that L-cells derived 256 
from murine organoids exhibited similar responses to L-cells in ileal primary cultures, thus 257 
validating the system as a good model for EEC research. This method is particularly exciting 258 
because organoids, like cell lines, can be genetically modified to produce lines with 259 
knockout, knockin and overexpression of genes of interest. Similar genetic manipulations of 260 
human derived organoids would give this technique unique advantages compared with 261 
other ex vivo and in vitro models.  262 
 263 
Interestingly, recent progress has been made in converting 3D organoid cultures to an open 264 
faced polarised epithelium that can be used for transport studies (41,42). One such 265 
technique has been shown to recapitulate the normal intestinal hierarchy and morphology, 266 
with the formation crypt/villus structures resembling in vivo tissue architecture (41). This 267 
method combined with genetically modified organoids will potentially open up new 268 
avenues for EEC research that are not currently possible with existing techniques.  269 
 270 
  271 
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Experimental Tools for EEC Research 272 
 273 
Hormone Secretion Studies 274 
The experimental models described above have been developed to study the mechanisms 275 
regulating hormone secretion in response to application of drugs or physiological stimuli. 276 
There is widespread interest in this field, because gut hormones have a variety of 277 
physiological roles, are currently exploited therapeutically for the treatment of type 2 278 
diabetes and obesity, and are under evaluation as future drug targets for a variety of 279 
metabolic and GI conditions. Hormones secreted by EECs have been measured by enzyme 280 
linked immunosorbent assays (ELISA), radioimmunoassays (RIA), mass-spectrometry, 281 
amperometry and by their effects on epithelial short circuit currents. 282 
 283 
Immuno-assays use antibodies directed against target peptides, linked to quantifiable 284 
outputs such as enzymatic reactions, radioisotopes or electroluminescent signals that are 285 
related to the quantity of antibody bound to the target peptide. The best immuno-assays 286 
have a very high sensitivity, which is essential for the analysis of gut hormone 287 
concentrations that typically range from 1-100 pg/ml in plasma. Nevertheless, an immuno-288 
assay is only as good as its component antibodies, which must have both high affinity and 289 
high specificity. These are typically tested by cross-reactivity experiments with other 290 
peptides as well as standard curve analysis using serial dilutions of target peptides. ELISAs 291 
have been successfully used to measure GLP-1, GIP, SST, neurotensin, serotonin and PYY 292 
secretion from a variety of ex vivo and in vitro models  (4,6,23,26,28,43). Drugs which 293 
directly target known secretory signalling pathways, including cAMP (IBMX, forskolin) and 294 
protein kinase C (PMA) are typically used as positive controls in hormone secretion 295 
experiments. 296 
 297 
As discussed above, individual EECs can produce multiple hormones, and an ideal detection 298 
method would therefore enable the parallel measurement of multiple hormones from the 299 
same sample. This can be achieved by multiple or multiplexed ELISAs, but the performance 300 
of multiple assays on the same sample is generally limited by cost and sample volumes, and 301 
many multiplexed assays still perform less well than when individual hormones are assayed 302 
separately. The use of liquid chromatography tandem mass spectrometry (LC-MS/MS) for 303 
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the detection of peptide hormones is an emerging field that enables the parallel detection 304 
of multiple hormones from a single sample (44,45). This is particularly useful for hormones 305 
such as INSL5, for which there are currently no reliable commercial immunoassays available 306 
(46). Using LC-MS, we could detect INSL5 secretion from primary human and mouse colonic 307 
cultures (44), and have simultaneously measured GLP-1, PYY and INSL5 release from human 308 
and mouse colonic cultures in response to a variety of drugs and physiological stimuli (47). 309 
LC-MS/MS analysis of hormone levels does come with some caveats compared to traditional 310 
ELISAs, including generally lower sensitivity and the need for modified peptides to be spiked 311 
into each sample to both account for loss during preparation and to accurately quantify the 312 
relevant hormone levels.  313 
 314 
Serotonin secretion from isolated enterochromaffin cells has been measured by ELISA or 315 
carbon fibre amperometry (14,28,29). Amperometry enables the detection of individual 316 
vesicular release events which trigger discrete currents in the carbon fibre electrode due to 317 
the oxidation of serotonin (29,48). 318 
 319 
 320 
Transgenic Mice 321 
The generation of transgenic reporter mice has enabled a dramatic increase in our 322 
understanding of EEC function and has helped to identify and validate a wide range of 323 
signalling pathways controlling hormone secretion from the intestine. Most genetically 324 
modified mouse models used in EEC research harness cell-specific promoters, such as the 325 
promoters for the hormones themselves (e.g. GLP-1, GIP, CCK, SST, ghrelin), chromogranin A, 326 
EEC-specific transcription factors (e.g.NeuroD1) or tryptophan hydroxylase (Tph1, required 327 
for serotonin biosynthesis) (Figure 3) (23,26,43,49-57). These EEC-specific promoters are 328 
used to drive cell-specific expression of fluorescent reporters/sensors or Cre-recombinase.  329 
Interestingly, the Chga-hrGFP reporter line seems specifically to label enterochromaffin cells 330 
even though ChgA is considered to be a marker of most EECs, although this mirrors our 331 
previous observation that ChgA staining was low in murine L-cells compared with other EECs 332 
(37,56).  333 
 334 
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When the fluorescent reporter is directly driven by a hormonal promoter, the detection of 335 
fluorescence in a cell should reflect current or recent activity of the hormonal promoter, as 336 
is seen with mouse strains such as GLU-Venus, GIP-GFP, CCK-GFP and ChgA-hrGFP 337 
(23,52,56,58). Hormone promoters driving Cre-recombinase, by contrast, are actually 338 
lineage tracers in the sense that even a brief activation of the hormone promoter and 339 
consequent transient expression of Cre-recombinase can activate Cre inducible elements in 340 
the DNA, causing permanent genetic changes that persist for the lifetime of the cell and are 341 
passed on to daughter cells. If Cre-expression is used to label an EEC population, it does not 342 
therefore necessarily reflect ongoing hormone expression. This can be useful when the 343 
endogenous cell-specific promoter is too weak itself to drive detectable fluorescence, 344 
because it is used instead to activate a fluorescent reporter that is driven by a much 345 
stronger promoter. Although, as with all indicators, one might be concerned that chronic 346 
overexpression of fluorescent reporters might be toxic or alter the dynamics of the 347 
monitored secondary messengers, we have not detected any differences in the 348 
responsiveness of our reporter lines to different secretory stimuli and observed similar Ca2+-349 
dynamics when monitoring with GCaMP3 or Fura-2. 350 
 351 
Transgenic mouse technologies have allowed researchers to identify the rare EEC cells 352 
amongst the rest of the intestinal epithelial cells, enabling application of a wide variety of 353 
analytical methods, including population and single cell transcriptomics, electrophysiology 354 
and single cell imaging of intracellular signalling pathways. 355 
 356 
Flow cytometry 357 
EECs expressing fluorescent reporters, derived from transgenic mouse models, can be 358 
readily separated from their non-fluorescent neighbours by fluorescence-assisted cell 359 
sorting (FACS) following dispersal of the mucosa by enzymatic digestion or EDTA (23). Flow 360 
cytometry gates set on forward scatter and side scatter enable the distinction between cells 361 
and debris, and an additional pulse width gate is useful to reduce the collection of cell 362 
clusters containing a single fluorescent EEC that appear on the FACS as a single large 363 
fluorescent cell. EEC populations of 90-95% purity can be achieved by FACS, with the major 364 
limiting feature being the quality of the single cell digest. Additional nuclear stains are 365 
frequently used to exclude dead cells.  366 
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 367 
Flow cytometry can also be used to analyse the proteins produced by individual EECs, in a 368 
method that involves fixation and antibody staining of cell suspensions following tissue 369 
dispersal (19). The technique enables the identification and quantification of EECs producing 370 
e.g. different hormonal combinations, or other high abundance proteins that are readily 371 
detectable using antibodies. We have also developed protocols to enable transcriptomic 372 
analysis of fixed and stained EECs following FACS purification, allowing the characterisation 373 
of non-murine species, including human, that do not carry transgenic markers (Roberts et al, 374 
manuscript under review). A similar approach has recently been reported for the isolation of 375 
murine chromaffin cells not relying on transgenic labelling (59). 376 
 377 
Transcriptomics 378 
FACS purified EECs have been analysed at the transcriptomic level by rt-qPCR to quantify 379 
pre-selected transcripts, and by microarrays and RNA seq to identify all transcripts. RNA 380 
sequencing methods are now sufficiently sensitive to permit analysis of single cells as well 381 
as cell populations, although single cell analysis is still limited by read-depth and the costs of 382 
analysing large numbers of cells individually. By these methods, it has been shown that 383 
primary EECs express a wide variety of G-protein coupled receptors (GPCRs), transporters 384 
and channels which have subsequently been shown to play roles in the function and 385 
physiology of EECs (23,37,60). Application of single cell RNA sequencing methods to 386 
investigate EECs was first achieved by random sampling of intestinal organoid cells (61) or 387 
primary cells (1) and more recently was applied to duodenual L-cells purified by FACS from 388 
the GLU-Venus mouse model (58). These data have highlighted the heterogeneity of EECs 389 
with regard to expression of multiple hormones and GPCRs. Enterochromaffin cells in 390 
organoids labelled with the ChgA-hrGFP reporter have also been investigated by rt-qPCR 391 
and RNA sequencing, to identify the channels/transporters and receptors that are 392 
differentially expressed compared with the non-fluorescent cell population (37).  393 
 394 
Electrophysiology 395 
Electrophysiology evaluates the flow of ions or potential difference across biological tissues, 396 
or cell membranes. In Ussing chambers, the short circuit current can be used as a measure 397 
of net ion transport across the epithelium and has been used to assess PYY secretion 398 
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triggered by nutrients, hormones and drugs (6,9). Locally released PYY binds to NPY1R 399 
receptors on enterocytes, thereby lowering intracellular cAMP concentrations and blocking 400 
apical chloride secretion which can be measured by changes in the short circuit current (8).  401 
 402 
Early patch clamp studies of STC-1 cells revealed the presence of voltage gated Ca2+ and K+ 403 
currents, but did not find any direct evidence that the cells fired action potentials (62). 404 
GLUTag cells, and EECs in primary cultures and organoids, by contrast, were found to be 405 
electrically active and capable of firing action potentials dependent on voltage gated Na+ 406 
and Ca2+ channels (23,36,37,60,63-67). The detection of electrical activity in GLUTag and 407 
primary L-cells likely reflects the use of perforated patch rather than whole cell recordings 408 
which retain a more physiological intracellular milieu. Indeed, EECs exhibit very high 409 
electrical resistance, and only small leak currents are sufficient to abolish action potential 410 
firing. Whilst patch clamping of colonic primary L-cells (identified using GLU-Venus mice) 411 
and GLUTag cells is relatively straight forward because colonic L-cells survive in culture for 412 
over a week (64,67), we found it considerably more difficult to patch clamp duodenal EECs 413 
in primary culture because they only survived for a few days, and produced substantial 414 
quantities of mucus that tended to block the electrodes. Organoid-derived ileal L-cells, 415 
however, proved a more robust system for patch clamping, revealing that ileal L-cells like 416 
their colonic counterparts fire action potentials that are modulated by external stimuli (36). 417 
Organoid-derived enterochromaffin cells from ChgA reporter mice also exhibited Na+ and 418 
Ca2+ dependent action potentials (37).  419 
 420 
Live cell imaging 421 
Fluorescent dyes and genetically encoded sensors have been used to monitor intracellular 422 
concentrations of Ca2+, cAMP and glucose in EECs in response to stimulus application. Cell 423 
permeant Ca2+ indicators such as Fura2-AM can be used to load an entire dish of cells, and 424 
have been employed to monitor Ca2+ in a variety of EEC cell lines (67-69). For primary EECs, 425 
however, extra steps must be incorporated that permit EEC identification amongst the 426 
mixture of other cell types, or include prior cell purification. CCK-expressing cells, for 427 
example, have been FACS purified from CCK-eGFP mice and loaded with the Ca2+ indicator 428 
Quest Rhod4, to show that CCK-producing cells exhibited Ca2+ responses to ligands of the 429 
free fatty acid receptor FFA1 (70), and enterochromaffin cells were purified by Percoll 430 
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gradients prior to Fluo-4 loading, to enable Ca2+ imaging of the enterochromaffin cell 431 
population (28-30). More recently, however, we have seen the introduction of genetically 432 
encoded sensors that incorporate a binding domain for the signal of interest, fused to one 433 
or more fluorescent molecules that exhibit altered fluorescence intensity or fluorescence 434 
resonance energy transfer (FRET) upon ligand binding (25,50,71). Genetically encoded 435 
sensors provide the advantage that they can be specifically expressed in the target cell of 436 
interest using transgenic technologies. ROSA26-GCaMP3 reporter mice, for example, 437 
express the Cre-dependent Ca2+ sensor GCaMP3, and can be crossed with mouse strains 438 
expressing Cre-recombinase under EEC-specific promoters to enable Ca2+ recordings in EEC 439 
populations of interest. Most genetic sensors have not, however, yet been incorporated into 440 
Cre-dependent mouse strains, but can be introduced into cell lines by standard transfection 441 
methods to enable monitoring of intracellular cAMP or glucose concentration (50,71). Use 442 
of these sensors in primary EECs requires an additional method for cell identification, such 443 
as a transgenic EEC-specific fluorescent reporter activated at wavelengths that do not 444 
interfere with the sensor, or prior cell purification by FACS. Expression of the genetic sensor 445 
can also be driven directly by an EEC promoter in a transgenic mouse model, as exemplified 446 
by GLU-Epac2-camps, which expresses the cAMP sensor Epac2-camps driven by the 447 
proglucagon promoter to allow cAMP monitoring in L-cells (49). These methods have 448 
enabled dynamic monitoring of GPCR signalling pathways in live EECs following stimulus 449 
application, assessment of net glucose fluxes, and Ca2+ changes downstream of Ca2+ influx 450 
or release from intracellular stores.  451 
 452 
 453 
Assessing physiological EEC stimuli by combined experimental techniques 454 
The models and experimental tools described above have been used to identify a wide 455 
range of stimulants and suppressors of gut hormone release, site of interaction of nutrients 456 
with EECs and some of the molecular pathways involved in nutrient detection and hormone 457 
secretion. Many of the findings from these studies are summarised in Figure 4. As an 458 
example of how the different techniques have been combined to explore a molecular 459 
pathway, we will consider the question of how bile acids trigger GLP-1 secretion. 460 
 461 
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Bile acids have been demonstrated to increase GLP-1 secretion from GLUTag cells, primary 462 
colonic L-cells, ileal organoid-derived L-cells, ileal tissue mounted in Ussing chambers and 463 
perfused intestine (2,5,10,36,72). Knock-down studies in GLUTag cells and the use of tissues 464 
from knock-out mice confirmed that the major receptor involved in the bile acid triggered 465 
GLP-1 secretion is the G-protein coupled bile acid receptor GPBAR1 (also known as TGR5), 466 
which is highly expressed in primary L-cells (2,72,73). Consistent with the known Gs 467 
coupling of GPBAR1, bile acids and the GPBAR1 agonist GPBAR-A increased intracellular 468 
cAMP levels in GLUTag cells transiently expressing the cAMP FRET sensor Epac2-camps, as 469 
well as in primary L-cells in organoids derived from the GLU-Epac2-camps mouse model 470 
(2,36,72). The use of 2D organoid cultures allowed electrophysiology assessment of the bile 471 
acid receptor in ileal L-cells, revealing that GPBAR1 agonism increased action potential firing 472 
and enhanced the activity of voltage gated Ca2+ channels, thereby potentiating Ca2+ signals 473 
triggered by FFA1 agonists, as measured in organoid L-cells from GLU-Cre/GCaMP3 mice 474 
(36). A key question for the potential translational exploitation of GPBAR1 as a drug target 475 
for increasing endogenous GLP-1 secretion is whether small molecule receptor agonists 476 
could target the receptor from the apical membrane, thus enabling the development of 477 
non-absorbable agonists with low side effect profiles. Ussing chamber and perfused 478 
intestine experiments, however, demonstrated that bile acids only enhance GLP-1 secretion 479 
following their absorption across the epithelium, and that non-absorbable GPBAR1 agonists 480 
are only effective when applied from the basolateral direction (2,5,10). Nevertheless, 481 
activation of GPBAR1, particularly in combination with FFA1, provides strong stimulus to L-482 
cells that deserves further exploration as a potential therapeutic strategy.  483 
 484 
Concluding Comments 485 
 486 
Compared with the situation 20 years ago, when studies on gut hormone secretion were 487 
largely restricted to the use of whole animals, perfused intestinal preparations, Ussing 488 
chamber recordings and cell lines, EEC research has exploded recently both in terms of the 489 
techniques and protocols available to researchers and our understanding of the molecular 490 
pathways employed by EECs for stimulus secretion and detection. The use of high 491 
throughput systems such as cell lines and primary cultures has enabled the identification of 492 
a wide range of nutrient and non-nutrient dependent pathways involved in the stimulation 493 
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and inhibition of hormone release. Increased use of intestinal organoids is hoped to 494 
facilitate more translational human based research and reduce the need for ex vivo animal 495 
based studies. The new technologies that use organoid cultures to generate an in vivo type 496 
intestinal architecture with intact barrier function provide promising new avenues for the 497 
study of human and murine EEC function. 498 
 499 
Figure legends 500 
Figure 1: Enteroendocrine cells and their hormones 501 
(a) Table listing the different EEC types and the main hormones/monoamines they produce. 502 
(b) Schematic showing an open-type EEC (blue) facing into the gut lumen, between 503 
neighbouring enterocytes in the intestinal epithelium, highlighting sites of stimulus 504 
detection and hormone (red) secretion.  505 
 506 
Figure 2 Ex vivo and in-vitro models for studying enteroendocrine cells 507 
(a) Table showing the different features and applications of ex vivo (isolated perfused 508 
intestine and Ussing chambers) and in vitro (primary cultures, isolated EECs, organoids) 509 
models described in the text. (b) Schematic of small intestine and colonic epithelium with 510 
the rare EECs (blue) found in both crypts and mature epithelium (villi and surface 511 
epithelium). (c-g) Diagrams showing the different model systems. (c) In isolated perfused 512 
intestine, solutions can be perfused via the intestinal lumen and vascular supply. (d) Ussing 513 
chamber setup, in which tissue forms a barrier between 2 compartments (integrity measure 514 
by electrodes). Solutions can be added to, and sampled from, either compartment. (e) 515 
Single cell digest of intestinal epithelium, enabling EECs to be isolated by FACS or Percoll 516 
density gradient. (f) Primary intestinal monolayers generated by epithelial digestion and 517 
seeding onto a matrix scaffold (black) to form a non-polarised monolayer in which EECs are 518 
intermixed with other epithelial cell types. (g) 3D intestinal organoid structures resembling 519 
in vivo architecture (crypt and villi domains) with polarised epithelium containing all cell 520 
types including EECs. 521 
 522 
Figure 3: Transgenic enteroendocrine cell models 523 
(a) Table listing the current transgenic models used to identify different EEC types. Glu-524 
Venus (green) mouse tissue showing colonic epithelium (b, image by L.Billing), an isolated 525 
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ileal villus (c) and isolated ileal crypts (d). Ileal organoid derived from Glu-Epac2-camps mice 526 
(e), with L-cells highlighted by Epac2-camps expression (green). Scale bar 100μm 527 
 528 
Figure 4: Mechanisms underlying glucose, SCFA, bile acid and amino acid sensing in 529 
enteroendocrine cells. 530 
(a) Glucose sensing in EECs, mediated by 2 pathways leading to cell depolarisation and 531 
opening of voltage gated calcium channels (VGCC), triggering Ca2+ influx and hormone 532 
secretion. Glucose co-transport with Na+ through apical SGLT1 can trigger depolarisation 533 
and secretion, whereas glucose influx via GLUT2 increases ATP levels and closes KATP 534 
channels, potentially modifying the effectiveness of other depolarising stimuli. (b) SCFA 535 
sensing in EECs mediated by FFA2 Gαq signalling, thereby increasing Ca2+ and triggering 536 
hormone release. An unidentified pathway might also trigger EEC depolarisation and 537 
opening of VGCC, as suggested by experiments on perfused intestine. (c) Bile acid sensing is 538 
mediated by basolateral GPBAR1 signalling through Gαs, increasing cAMP and triggering 539 
hormone secretion. GPBAR1 activation also promotes depolarisation and opening of VGCC. 540 
(d) Amino acid sensing in EECs is mediated by multiple pathways. Highlighted here are CASR 541 
Gαq signalling and electrogenic amino-acid uptake which trigger subsequent depolarisation 542 
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G-cells Gastrin 




EEC nutrient sensing 

















































































































































































X X X X X X hrs 
Ussing Chambers X X X X X X hrs 
Primary 
Monolayer 
X X X X X X days 
Isolated EECs X X X X days 
Organoids X X X X X X X X years 
Organoid derived 
monolayer 
X X X X X X days 




Add solutions / 
drugs to chamber 
Measure 
hormones 













































CCK I-cells Cck-GFP (53) 
SST D-cells Sst-Cre (43) 
5-HT EC-cells Tph1-CFP (54) 
Ghrelin X/A like Ghrelin-hrGFP (55) 





Colonic Epithelium b 
mGlu-Venus mGlu-Venus 
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